The surgical robot experts at Medtech are announcing that the company has received official authorization to market its ROSA robot in Australia for minimally invasive surgical procedures on the brain, and also spine surgery.
Medtech: Green Light to Market ROSA Robot

“This is an important milestone in the company’s development and ongoing expansion of our market opportunity. This authorization to market ROSA in Australia and the signing of a distribution agreement with Surgicom is a reflection of our strategy to increase our commercial presence at international level, including the Asia-Pacific region, where we already have strong momentum, ” commented Bertin Nahum, President, CEO and Founder of Medtech, in the May 18, 2015 news release.
Nahum told OTW, “We are very pleased to report that we have seen a notable uptick in the global adoption of ROSA surgical robots. The sale of eight surgical units in the first five months of 2015 now brings the total number of robots in use up to 41 worldwide. We hope the dynamism we are seeing in the U.S. market continues with the FDA clearance of ROSA Spine later this year. In the coming year we aim to drive adoption of both ROSA Brain and ROSA Spine globally, with specific focus in U.S. and Asian markets.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.